ProHance to Lead Key Discussions at Shared Services & Outsourcing Week (SSOW) 2025 in Orlando
ProHance leaders to share insights on GBS, shared services versatility & talent transformation at SSOW 2025 Orlando with workshops, panels & expert discussions.
ORLANDO, FL, UNITED STATES, March 20, 2025 / EINPresswire.com / -- ProHance, a new-age workplace analytics and operations enablement platform, is set to take center stage at the Shared Services & Outsourcing Week (SSOW) 2025 in Orlando. With a strong presence at the event, ProHance will deliver three impactful sessions featuring its leadership alongside industry experts.
These sessions will offer strategic insights into building agile shared services models, leveraging empirical data for GBS transformation, and reimagining talent management in the digital era.
Featured Sessions
Panel Discussion: Transforming Talent Management for the Digital Future
Date: March 24, 2025
Time: 2:00 PM
Panelist: Khiv Singh, Senior Vice President & Head of Americas, ProHance
Additional Panelists:
Sue Dempsey, SVP, Acrisure Business Services, Acrisure
Jack Deem, Assistant Controller, Con Edison
Jim Thomsen, VP of Customer Care, Showdown Displays
Mike Kresge, VP of Controller Shared Services, Leidos
As organizations navigate rapid digital transformation, effective talent management is crucial to sustaining competitive advantage. This panel will explore best practices for attracting, developing, and retaining a future-ready workforce equipped with digital expertise and problem-solving capabilities.
Key discussion points include:
- Identifying critical skills required for future-proof teams
- Balancing technical expertise with creativity to enhance productivity
- Implementing upskilling and engagement strategies to drive talent retention
- Aligning corporate culture with workforce transformation for long-term success
Workshop: Building Shared Services Versatility – Balancing Depth and Breadth in a Fast-Paced Environment
Date: March 25, 2025
Time: 9:00 AM
Speakers:
Ankur Dhingra, CEO, ProHance
Fabiano Lopes, VP, Cardinal Health
This workshop will provide an in-depth exploration of strategies to enhance the agility of shared services operations by balancing specialization with flexibility. As businesses evolve, organizations must adopt a model that seamlessly integrates depth and breadth to maximize efficiency and adaptability.
Key takeaways will include:
- Building operational resilience through a balanced skills and service model
- Scaling shared services functions while maintaining efficiency and agility
- Leveraging advanced technology and workforce analytics for optimal service delivery
Track Session: The Hidden Catalyst in GBS Transformation – Trustworthy, Empirical Data
Date: March 26, 2025
Time: 3:00 PM
Speakers:
Ankur Dhingra, CEO, ProHance
Fabiano Lopes, VP, Cardinal Health
Data-driven decision-making is a cornerstone of modern GBS transformation. This session will highlight how empirical data fosters trust, enhances operational efficiency, and accelerates business transformation.
Attendees will gain insights into:
- The role of real-time analytics and performance data in driving transformation
- The importance of transparency and data integrity in building stakeholder confidence
- Case studies demonstrating the tangible impact of data-driven GBS strategies
About ProHance
ProHance empowers organizations with a comprehensive suite of tools and capabilities designed to elevate productivity, enforce compliance, optimize costs, enhance customer satisfaction, enable data-driven decision-making, and seamlessly adapt to evolving business needs.
Currently deployed by over 400,000+ users across 25 countries, ProHance provides cutting-edge solutions that help businesses achieve strategic objectives and operational excellence.
For more information, visit www.prohance.net.
X
LinkedIn
Instagram
YouTube
Other
Legal Disclaimer:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
13 hours ago
- Business Insider
Cardinal Health (CAH) Gets a Buy from Mizuho Securities
In a report released today, Steven Valiquette from Mizuho Securities maintained a Buy rating on Cardinal Health (CAH – Research Report), with a price target of $161.00. The company's shares opened today at $153.54. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Valiquette covers the Healthcare sector, focusing on stocks such as Align Tech, Cencora, and DENTSPLY SIRONA. According to TipRanks, Valiquette has an average return of 0.4% and a 54.81% success rate on recommended stocks. Cardinal Health has an analyst consensus of Strong Buy, with a price target consensus of $165.73, a 7.94% upside from current levels. In a report released on June 3, Leerink Partners also reiterated a Buy rating on the stock with a $177.00 price target.
Associated Press
3 days ago
- Associated Press
Cardinal Health launches new medical device for the continuous monitoring of three essential vital signs in one system
Kendall DL™ Multi System simplifies patient monitoring, drives efficiencies for providers DUBLIN, Ohio, June 4, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today the U.S. launch of its multi-parameter, single-patient use monitoring cable and lead wire system that enables the continuous monitoring of cardiac activity, blood oxygen level and temperature with one point of connection. The new Kendall DL™ Multi System is designed to travel with the patient from admission to discharge for smooth transport. It helps improve clinician workflows, provides reliable monitoring to help determine the best course of care, and maximizes value across the hospital. 'This innovative addition to the Kendall DL portfolio removes complexity for busy care teams, and at the same time, helps enhance clinical performance with multi-parameter monitoring,' said Rachel Schott, global vice president for specialty products at Cardinal Health. 'The product streamlines steps that clinicians must follow to provide effective care and controls common lead wire clutter with its built-in cable management system.' The Kendall DL™ Multi System offers a proprietary design that features clinically proven technology to reduce the incidence of false 'leads off' alarms2 (i.e., indications that wires connected to the patient's body are not properly connected), as well as motion-related artifacts in electrocardiogram (ECG) tracings,† which are recorded disturbances due to a patient's movement. This yields cleaner ECG tracings and allows clinicians to more effectively prioritize the care they need to administer. As a single-patient use product, the system helps reduce cross contamination related to reusable lead wires for the monitoring of cardiac activity, blood oxygen level and temperature.1 This helps lower the chance of infection and the need for additional hospital days or readmissions.3 The system is eligible for medical device reprocessing through Cardinal Health. 'By enabling more efficient workflows and driving clinical excellence, this new solution can potentially support the financial performance of healthcare providers,' Schott said. 'Expanding our Kendall DL offerings demonstrates our commitment to providing products designed to address multiple clinical and operational challenges across healthcare organizations, and builds upon our legacy of safe, high-quality patient monitoring solutions providers have come to trust.' The Kendall DL™ Multi System is now available for health systems in the U.S. For more information, please visit us here. About Cardinal Health Cardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nuclear pharmacies and manufacturing facilities; and a provider of performance and data solutions. Our company's customer-centric focus drives continuous improvement and leads to innovative solutions that improve people's lives every day. Learn more about Cardinal Health at and in our Newsroom. Contacts References: †Cardinal Health Data on File – OEM Grabber Comparisons Report, Dec 2024 1. Brown DQ. Disposable vs reusable electrocardiography leads in development of and cross contamination by resistant bacteria. Crit Care Nurse. 2011 Jun;31(3):62 8. doi: 10.4037/ccn2011874. PMID: 21632593. 2. Albert N, Murray T, Bena J, et al. Differences in alarm events between disposable and reusable electrocardiography lead wires. Am J Crit Care. 2015 Jan;24(1):67-73; quiz 74. doi: 10.4031/ajcc2015663. 3. Saunders R, Hansson Hedblom A. The economic implications of introducing single patient ECG systems for cardiac surgery in Australia. Clinicoecon Outcomes Res. 2021 Aug 13;13:727-735. doi: 10.2147/CEOR.S232527 View original content to download multimedia: SOURCE Cardinal Health
Yahoo
4 days ago
- Yahoo
bioAffinity Technologies Works With Cardinal Health™ OptiFreight® Logistics to Help Meet Demand for CyPath® Lung
SAN ANTONIO, June 03, 2025--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics and targeted therapeutics for cancer, today announced publication of "The Drive for Early Detection," a case study detailing how bioAffinity Technologies utilizes support from Cardinal Health™ OptiFreight® Logistics to help meet demand for CyPath® Lung, a noninvasive test for detection of early stage lung cancer. "Our innovative, accurate diagnostic for lung cancer relies on dependable, on-time delivery of viable sputum samples to our laboratory for processing and providing reliable results to patients and their physicians," bioAffinity President and CEO Maria Zannes said. "CyPath® Lung has a strategic logistics partner in OptiFreight® Logistics who works with us to solve challenges, reduce costs, and continuously improve performance. They have the expertise and national reach to help ensure we meet the growing commercial demand for our test." bioAffinity uses information from Cardinal Health™ OptiFreight® Logistics TotalVue™ Insights, a cloud-based platform that provides shipment tracking, data analytics and reporting, to help address shipping challenges and identify opportunities to improve logistics. "We are pleased to work with bioAffinity to help advance their mission in providing patients with access to early-stage lung cancer detection," said Emily Gallo, Senior Vice President and General Manager of Cardinal Health™ OptiFreight® Logistics. "Our collaboration helps to ensure vital samples are delivered reliably and efficiently, enabling timely diagnoses that can make a real difference in the lives of patients." "With the growing demand for CyPath® Lung – including availability to veterans in rural areas through the Federal Supply Schedule and GSA Advantage – reliable, efficient shipping is more important than ever," Zannes said. "OptiFreight® Logistics provides near real-time alerts on weather disruptions and processing delays, enabling the CyPath® Lung lab to adjust collection schedules and avoid delivery failures. Our partnership with OptiFreight® helps ensure the success of our national expansion." To read the case study, visit Ms. Zannes will also be a panelist on the Cardinal Health™ OptiFreight® Logistics webinar, "Seeing a better way: Increasing visibility to optimize healthcare logistics," at 2 p.m. ET on June 12. Register here for the webinar. About CyPath® Lung CyPath® Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated that CyPath® Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage lung cancer can improve outcomes and increase patient survival. For more information, visit About bioAffinity Technologies, Inc. bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company's first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding bioAffinity advancing its mission to provide patients with access to early-stage lung cancer detection; the collaboration helping to ensure sputum samples are delivered reliably and efficiently, enabling timely diagnoses that can make a real difference in the lives of patients; and the partnership with OptiFreight® helping to ensure the success of the Company's national expansion. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability of the Company to successfully expand nationally; ensure sputum samples are delivered reliably and efficiently, enabling timely diagnoses that can make a real difference in the lives of patients; the ability to advance its mission to provide patients with access to early-stage lung cancer detection; and the other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws. View source version on Contacts bioAffinity Technologies Julie Anne OvertonDirector of Communicationsjao@ Investor Relations Dave GentryRedChip Companies Inc.1-800-RED-CHIP (733-2447) or 407-491-4498BIAF@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
